Fuyao Yang1, Jie Wang1, Weihao Li1, Yuanwei Xu1, Ke Wan2, Rui Zeng3, Yucheng Chen4,5. 1. Department of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China. 2. Department of Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, People's Republic of China. 3. Department of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China. zengrui_0524@126.com. 4. Department of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China. chenyucheng2003@126.com. 5. Center of Rare diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, People's Republic of China. chenyucheng2003@126.com.
Abstract
OBJECTIVE: To evaluate the prognostic value of late gadolinium enhancement (LGE) in myocarditis and clinically suspected myocarditis. METHODS: The study was registered in PROSPERO (CRD42019144976). A systematic search of PubMed, Ovid Medline, Embase, Web of Science and the Cochrane Central Register of Controlled Trials was completed. Major adverse cardiac event (MACE) was defined as the combination of all-cause mortality or cardiovascular death, resuscitated cardiac arrest, heart transplantation, appropriate implantable cardioverter-defibrillator shock, rehospitalisation following a cardiac event and recurrent acute myocarditis. Combined outcome was defined as the combination of all adverse events. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of LGE. RESULTS: Eight articles including 1319 patients (mean age, 38.8 ± 12.9 years) were included in the meta-analysis. The study showed that positive LGE was strongly associated with an increased risk of combined outcome (pooled OR, 5.85; 95% CI, 2.88 to 11.86; p < 0.001) and of MACE (pooled OR, 4.57; 95% CI, 2.18 to 9.59; p < 0.001). Additionally, in a subgroup analysis with mean ejection fraction (EF) point of 50%, the pooled ORs for the combined outcome were 6.46 for left ventricular EF (LVEF) > 50% and 7.90 for LVEF ≤ 50%, and the pooled ORs for MACE were 9.03 and 3.45, respectively. After 3 years of follow-up, the worse outcomes occurred mainly in patients with positive LGE. CONCLUSION: Positive LGE is a powerful prognosticator of adverse outcome in myocarditis and clinically suspected myocarditis, irrespective of LVEF. KEY POINTS: • Forty-four percent to 100% of myocarditis patients have positive late gadolinium enhancement. • Positive LGE was a powerful prognosticator of adverse outcome in myocarditis and clinically suspected myocarditis, irrespective of LVEF. • LGE-CMR is important tool for risk stratification in myocarditis and clinically suspected myocarditis.
OBJECTIVE: To evaluate the prognostic value of late gadolinium enhancement (LGE) in myocarditis and clinically suspected myocarditis. METHODS: The study was registered in PROSPERO (CRD42019144976). A systematic search of PubMed, Ovid Medline, Embase, Web of Science and the Cochrane Central Register of Controlled Trials was completed. Major adverse cardiac event (MACE) was defined as the combination of all-cause mortality or cardiovascular death, resuscitated cardiac arrest, heart transplantation, appropriate implantable cardioverter-defibrillator shock, rehospitalisation following a cardiac event and recurrent acute myocarditis. Combined outcome was defined as the combination of all adverse events. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of LGE. RESULTS: Eight articles including 1319 patients (mean age, 38.8 ± 12.9 years) were included in the meta-analysis. The study showed that positive LGE was strongly associated with an increased risk of combined outcome (pooled OR, 5.85; 95% CI, 2.88 to 11.86; p < 0.001) and of MACE (pooled OR, 4.57; 95% CI, 2.18 to 9.59; p < 0.001). Additionally, in a subgroup analysis with mean ejection fraction (EF) point of 50%, the pooled ORs for the combined outcome were 6.46 for left ventricular EF (LVEF) > 50% and 7.90 for LVEF ≤ 50%, and the pooled ORs for MACE were 9.03 and 3.45, respectively. After 3 years of follow-up, the worse outcomes occurred mainly in patients with positive LGE. CONCLUSION: Positive LGE is a powerful prognosticator of adverse outcome in myocarditis and clinically suspected myocarditis, irrespective of LVEF. KEY POINTS: • Forty-four percent to 100% of myocarditispatients have positive late gadolinium enhancement. • Positive LGE was a powerful prognosticator of adverse outcome in myocarditis and clinically suspected myocarditis, irrespective of LVEF. • LGE-CMR is important tool for risk stratification in myocarditis and clinically suspected myocarditis.
Entities:
Keywords:
Fibrosis; Magnetic resonance imaging; Meta-analysis; Myocarditis; Prognosis
Authors: Ornella Leone; John P Veinot; Annalisa Angelini; Ulrik T Baandrup; Cristina Basso; Gerald Berry; Patrick Bruneval; Margaret Burke; Jagdish Butany; Fiorella Calabrese; Giulia d'Amati; William D Edwards; John T Fallon; Michael C Fishbein; Patrick J Gallagher; Marc K Halushka; Bruce McManus; Angela Pucci; E René Rodriguez; Jeffrey E Saffitz; Mary N Sheppard; Charles Steenbergen; James R Stone; Carmela Tan; Gaetano Thiene; Allard C van der Wal; Gayle L Winters Journal: Cardiovasc Pathol Date: 2011-12-03 Impact factor: 2.185
Authors: Stefan Grün; Julia Schumm; Simon Greulich; Anja Wagner; Steffen Schneider; Oliver Bruder; Eva-Maria Kispert; Stephan Hill; Peter Ong; Karin Klingel; Reinhardt Kandolf; Udo Sechtem; Heiko Mahrholdt Journal: J Am Coll Cardiol Date: 2012-02-22 Impact factor: 24.094
Authors: Sujith Kuruvilla; Nebiyu Adenaw; Arabindra B Katwal; Michael J Lipinski; Christopher M Kramer; Michael Salerno Journal: Circ Cardiovasc Imaging Date: 2013-12-20 Impact factor: 7.792
Authors: Matthias G Friedrich; Udo Sechtem; Jeanette Schulz-Menger; Godtfred Holmvang; Pauline Alakija; Leslie T Cooper; James A White; Hassan Abdel-Aty; Matthias Gutberlet; Sanjay Prasad; Anthony Aletras; Jean-Pierre Laissy; Ian Paterson; Neil G Filipchuk; Andreas Kumar; Matthias Pauschinger; Peter Liu Journal: J Am Coll Cardiol Date: 2009-04-28 Impact factor: 24.094
Authors: Giuseppe Gargiulo; Andreas Goette; Jan Tijssen; Lars Eckardt; Thorsten Lewalter; Pascal Vranckx; Marco Valgimigli Journal: Eur Heart J Date: 2019-12-07 Impact factor: 29.983
Authors: Ji Won Lee; Yeon Joo Jeong; Geewon Lee; Nam Kyung Lee; Hye Won Lee; Jin You Kim; Bum-Sung Choi; Ki Seok Choo Journal: Korean J Radiol Date: 2017-05-19 Impact factor: 3.500
Authors: Rupal O'Quinn; Victor A Ferrari; Ryan Daly; Greg Hundley; Lauren A Baldassarre; Yuchi Han; Ana Barac; Anita Arnold Journal: JACC CardioOncol Date: 2021-06-15
Authors: Moritz Mirna; Lukas Schmutzler; Albert Topf; Elke Boxhammer; Brigitte Sipos; Uta C Hoppe; Michael Lichtenauer Journal: J Cardiovasc Dev Dis Date: 2022-01-19
Authors: Saurabh Rajpal; Rami Kahwash; Matthew S Tong; Kelly Paschke; Anjali A Satoskar; Beth Foreman; Larry A Allen; Nicole M Bhave; Ty J Gluckman; Valentin Fuster Journal: J Am Coll Cardiol Date: 2022-03-29 Impact factor: 27.203
Authors: Saurabh Rajpal; Rami Kahwash; Matthew S Tong; Kelly Paschke; Anjali A Satoskar; Beth Foreman; Larry A Allen; Nicole M Bhave; Ty J Gluckman; Valentin Fuster Journal: JACC Case Rep Date: 2022-03-29